Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns
- 4 July 2024
- journal article
- research article
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (10) , 1448-1453
Abstract
Objective The use of vasopressin as an adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension has increased. The objective of our study is to describe its effects on term infants. Study design Retrospective observational study. Setting in a referral level IV neonatal intensive care unit from a middle-income region. The patients are term neonates admitted to our NICU who required vasopressin due to severe Pulmonary Hypertension and refractory hypotension during a 49-month period (December 2019 and December 2023). Results We identified 68 term infants, all in mechanical ventilation, receiving inhaled nitric oxide (iNO), and a phased protocol management for hypotension. Vasopressin was a started at a mean of 2 days with a mean duration of 80 h. Regarding hemodynamic outcome: diastolic, systolic, and median systemic pressure significantly increased during the first 4 h of treatment, as well as arterial pH and urine output. Accordingly, lactate and Vasoactive Inotropic Score (VIS) score decreased after 4 and 8 h, respectively, after vasopressin was started. Regarding oxygenation markers: oxygen requirements and mean airway pressure decreased significantly (and therefore the oxygenation index decreased in concordance) after 4 h of vasopressin. Echocardiographic indices of pulmonary hypertension progressively improved after vasopressin infusion with a significant decrease of tricuspid ingurgitation velocities and the rate of right-to- left ductal shunt through the ductus arteriosus. In the same way, left and right ventricular output increased after the initiation of vasopressin. Conclusion This study showed that the use of vasopressin in neonates with persistent pulmonary hypertension was associated with a rapid and significant improvement in oxygenation and hemodynamic markers of perfusion, including blood pressure. Its effects begin early during the first hours of treatment.Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018The Journal of Pediatrics, 2021
- Effect of Vasopressin on Systemic and Pulmonary Hemodynamics in NeonatesAmerican Journal of Perinatology, 2020
- Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis*Pediatric Critical Care Medicine, 2017
- Vasopressin Improves Hemodynamic Status in Infants with Congenital Diaphragmatic HerniaThe Journal of Pediatrics, 2014
- Vasopressin as a Rescue Therapy for Refractory Pulmonary Hypertension in NeonatesPediatric Critical Care Medicine, 2014
- Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysisIntensive Care Medicine, 2011
- Vasopressin for Refractory Hypotension in Extremely Low Birth Weight InfantsThe Journal of Pediatrics, 2010
- Treatment of Refractory Hypotension With Low-Dose Vasopressin in a Patient Receiving ClozapineJournal of Cardiothoracic and Vascular Anesthesia, 2010
- Vasopressin and its role in critical careContinuing Education in Anaesthesia Critical Care & Pain, 2008
- Diagnostic criteria and therapeutic interventions for the hypotensive very low birth weight infantJournal of Perinatology, 2006